Stifel Nicolaus Reconfirms $55 PT On Ionis Pharmaceuticals (IONS), Reconfirms Hold Rating; Clover Partners LP Trimmed Pacific Mercantile Bancorp (PMBC) Stake

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

Clover Partners Lp decreased Pacific Mercantile Bancorp (PMBC) stake by 61.79% reported in 2017Q4 SEC filing. Clover Partners Lp sold 927,384 shares as Pacific Mercantile Bancorp (PMBC)’s stock rose 6.82%. The Clover Partners Lp holds 573,538 shares with $5.02M value, down from 1.50 million last quarter. Pacific Mercantile Bancorp now has $224.97 million valuation. The stock increased 0.52% or $0.05 during the last trading session, reaching $9.65. About 6,828 shares traded. Pacific Mercantile Bancorp (NASDAQ:PMBC) has risen 23.68% since May 7, 2017 and is uptrending. It has outperformed by 12.13% the S&P500.

Expert analysts at Stifel Nicolaus have $55 target price on Ionis Pharmaceuticals (IONS). Stifel Nicolaus’s target price would indicate a potential upside of 24.97% from the company’s previous close. The rating was revealed in an analyst report on 7 May.

Since December 11, 2017, it had 3 buys, and 8 sales for $171,573 activity. FINLEY WARREN T sold $62,383 worth of stock or 6,505 shares. 405 shares were sold by THOMAS JOHN MD, worth $3,443 on Friday, March 2. $31,332 worth of stock was bought by Inserra Thomas J. on Wednesday, January 31. GRAY NANCY A had sold 7,000 shares worth $63,700 on Thursday, March 8. VERITY CINDY also sold $11,690 worth of Pacific Mercantile Bancorp (NASDAQ:PMBC) on Wednesday, February 21. 7,400 shares were bought by Vertin Thomas, worth $63,550. 1,515 shares were sold by Wagner Tom, worth $12,256.

More recent Pacific Mercantile Bancorp (NASDAQ:PMBC) news were published by: Nasdaq.com which released: “Pacific Mercantile Bancorp to Participate in the DA Davidson Financial Institutions Conference” on May 03, 2018. Also Globenewswire.com published the news titled: “Pacific Mercantile Bancorp Reports First Quarter 2018 Operating Results” on April 23, 2018. Globenewswire.com‘s news article titled: “Jim Roby Appointed Director of SBA Lending at Pacific Mercantile Bank” with publication date: April 11, 2018 was also an interesting one.

Investors sentiment increased to 1.39 in 2017 Q4. Its up 0.45, from 0.94 in 2017Q3. It is positive, as 2 investors sold PMBC shares while 16 reduced holdings. 9 funds opened positions while 16 raised stakes. 10.16 million shares or 8.95% less from 11.16 million shares in 2017Q3 were reported. Ameritas Prtn holds 0% or 1,193 shares in its portfolio. Parametric Llc stated it has 20,992 shares. Legal & General Group Plc accumulated 2,422 shares. Moreover, First Foundation Advsrs has 0.01% invested in Pacific Mercantile Bancorp (NASDAQ:PMBC). State Street owns 0% invested in Pacific Mercantile Bancorp (NASDAQ:PMBC) for 218,990 shares. Parallax Volatility Advisers LP holds 0% or 2,646 shares. Cornerstone Cap Mgmt Holdg Ltd Liability Co has invested 0% in Pacific Mercantile Bancorp (NASDAQ:PMBC). Acadian Asset Mgmt Ltd Liability has invested 0% in Pacific Mercantile Bancorp (NASDAQ:PMBC). Schwab Charles Investment holds 0% or 21,300 shares. Bnp Paribas Arbitrage holds 4,071 shares. 47,000 were reported by Salzhauer Michael. Barclays Public Limited Company has invested 0% in Pacific Mercantile Bancorp (NASDAQ:PMBC). Vanguard Gp Incorporated has invested 0% in Pacific Mercantile Bancorp (NASDAQ:PMBC). Northern Tru Corp invested in 155,156 shares. Alliancebernstein Ltd Partnership holds 0% or 250,916 shares.

Among 3 analysts covering Pacific Mercantile Bancorp (NASDAQ:PMBC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pacific Mercantile Bancorp had 7 analyst reports since May 26, 2017 according to SRatingsIntel. The stock of Pacific Mercantile Bancorp (NASDAQ:PMBC) has “Hold” rating given on Friday, May 26 by Keefe Bruyette & Woods. The stock has “Buy” rating by Hovde Group on Wednesday, March 21. The stock of Pacific Mercantile Bancorp (NASDAQ:PMBC) has “Buy” rating given on Tuesday, January 30 by Hovde Group. The firm has “Buy” rating by Keefe Bruyette & Woods given on Thursday, December 21. Keefe Bruyette & Woods upgraded the stock to “Buy” rating in Thursday, August 3 report. As per Tuesday, April 24, the company rating was maintained by Keefe Bruyette & Woods. The stock of Pacific Mercantile Bancorp (NASDAQ:PMBC) has “Outperform” rating given on Thursday, August 3 by Wood.

The stock increased 6.64% or $2.74 during the last trading session, reaching $44.01. About 1.98 million shares traded or 61.35% up from the average. Ionis Pharmaceuticals, Inc. (IONS) has risen 14.82% since May 7, 2017 and is uptrending. It has outperformed by 3.27% the S&P500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $5.52 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: Streetinsider.com which released: “There Are Better Ideas Than Ionis Pharma (IONS) – Goldman Sachs” on May 07, 2018, also Seekingalpha.com with their article: “Ionis Pharma Q1 revenues up 25%” published on May 04, 2018, Seekingalpha.com published: “Ionis Pharmaceuticals’ (IONS) CEO Stan Crooke on Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More” published on May 06, 2018 as well as Seekingalpha.com‘s news article titled: “Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation” with publication date: April 30, 2018.

Among 14 analysts covering Ionis Pharmace… (IONS), 6 have Buy rating, 1 Sell and 7 Hold. Therefore 43% are positive. Ionis Pharmace… has $7500 highest and $25 lowest target. $54.75’s average target is 24.40% above currents $44.01 stock price. Ionis Pharmace… had 41 analyst reports since April 7, 2016 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, November 8. BMO Capital Markets maintained the shares of IONS in report on Friday, August 11 with “Buy” rating. The stock has “Buy” rating by Needham on Friday, September 15. The firm has “Buy” rating given on Monday, October 16 by Needham. The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) earned “Buy” rating by BMO Capital Markets on Thursday, March 15. As per Thursday, April 7, the company rating was initiated by BMO Capital Markets. BMO Capital Markets maintained it with “Outperform” rating and $65 target in Wednesday, February 28 report. The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has “Buy” rating given on Tuesday, December 27 by Laidlaw. BMO Capital Markets maintained Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Monday, April 23 with “Outperform” rating. The stock has “Outperform” rating by BMO Capital Markets on Thursday, October 6.

Analysts await Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report earnings on May, 8. They expect $-0.11 earnings per share, down 466.67% or $0.14 from last year’s $0.03 per share. After $0.02 actual earnings per share reported by Ionis Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -650.00% negative EPS growth.

Pacific Mercantile Bancorp (NASDAQ:PMBC) Institutional Positions Chart